At-Risk Launches: Three Cases May Determine How Damages Are Calculated
How risky are at-risk launches of generic products?
You may also be interested in...
Purdue's OxyContin and Amarin's Vascepa lead the list of targets as an increasing number of generic firms take up litigation.
With a large chunk of its cash reserves spent to settle the Protonix patent case, India’s Sun Pharma may no longer be in position to follow its inorganic growth plans.
Teva and India’s Sun Pharma are to pay $2.15 billion for their at-risk launch in the U.S. of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.